Emergent Biosolutions Debt to Equity Ratio 2010-2023 | EBS
Current and historical debt to equity ratio values for Emergent Biosolutions (EBS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Emergent Biosolutions debt/equity for the three months ending March 31, 2023 was 0.37.
| Emergent Biosolutions Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-03-31 |
$1.75B |
$1.20B |
1.45 |
| 2022-12-31 |
$1.78B |
$1.38B |
1.29 |
| 2022-09-30 |
$1.46B |
$1.45B |
1.01 |
| 2022-06-30 |
$1.22B |
$1.51B |
0.81 |
| 2022-03-31 |
$1.21B |
$1.58B |
0.77 |
| 2021-12-31 |
$1.34B |
$1.62B |
0.83 |
| 2021-09-30 |
$1.35B |
$1.52B |
0.88 |
| 2021-06-30 |
$1.37B |
$1.54B |
0.89 |
| 2021-03-31 |
$1.38B |
$1.52B |
0.90 |
| 2020-12-31 |
$1.44B |
$1.45B |
0.99 |
| 2020-09-30 |
$1.37B |
$1.25B |
1.09 |
| 2020-06-30 |
$1.27B |
$1.20B |
1.06 |
| 2020-03-31 |
$1.20B |
$1.08B |
1.12 |
| 2019-12-31 |
$1.24B |
$1.09B |
1.14 |
| 2019-09-30 |
$1.30B |
$1.04B |
1.26 |
| 2019-06-30 |
$1.33B |
$0.99B |
1.35 |
| 2019-03-31 |
$1.17B |
$0.99B |
1.18 |
| 2018-12-31 |
$1.22B |
$1.01B |
1.21 |
| 2018-09-30 |
$0.21B |
$0.97B |
0.21 |
| 2018-06-30 |
$0.20B |
$0.94B |
0.21 |
| 2018-03-31 |
$0.19B |
$0.88B |
0.21 |
| 2017-12-31 |
$0.16B |
$0.91B |
0.17 |
| 2017-09-30 |
$0.36B |
$0.66B |
0.54 |
| 2017-06-30 |
$0.35B |
$0.62B |
0.56 |
| 2017-03-31 |
$0.34B |
$0.61B |
0.56 |
| 2016-12-31 |
$0.37B |
$0.60B |
0.63 |
| 2016-09-30 |
$0.38B |
$0.55B |
0.70 |
| 2016-06-30 |
$0.38B |
$0.67B |
0.57 |
| 2016-03-31 |
$0.37B |
$0.67B |
0.55 |
| 2015-12-31 |
$0.38B |
$0.66B |
0.57 |
| 2015-09-30 |
$0.37B |
$0.61B |
0.61 |
| 2015-06-30 |
$0.38B |
$0.56B |
0.68 |
| 2015-03-31 |
$0.38B |
$0.54B |
0.71 |
| 2014-12-31 |
$0.39B |
$0.55B |
0.70 |
| 2014-09-30 |
$0.36B |
$0.51B |
0.69 |
| 2014-06-30 |
$0.35B |
$0.49B |
0.72 |
| 2014-03-31 |
$0.35B |
$0.48B |
0.72 |
| 2013-12-31 |
$0.14B |
$0.49B |
0.28 |
| 2013-09-30 |
$0.13B |
$0.47B |
0.28 |
| 2013-06-30 |
$0.11B |
$0.45B |
0.24 |
| 2013-03-31 |
$0.10B |
$0.44B |
0.24 |
| 2012-12-31 |
$0.12B |
$0.44B |
0.28 |
| 2012-09-30 |
$0.11B |
$0.43B |
0.26 |
| 2012-06-30 |
$0.11B |
$0.42B |
0.25 |
| 2012-03-31 |
$0.10B |
$0.41B |
0.25 |
| 2011-12-31 |
$0.13B |
$0.42B |
0.31 |
| 2011-09-30 |
$0.13B |
$0.39B |
0.33 |
| 2011-06-30 |
$0.11B |
$0.38B |
0.30 |
| 2011-03-31 |
$0.11B |
$0.36B |
0.31 |
| 2010-12-31 |
$0.13B |
$0.37B |
0.34 |
| 2010-09-30 |
$0.09B |
$0.28B |
0.31 |
| 2010-06-30 |
$0.08B |
$0.26B |
0.32 |
| 2010-03-31 |
$0.09B |
$0.25B |
0.38 |
| 2009-12-31 |
$0.10B |
$0.24B |
0.41 |
| 2009-09-30 |
$0.08B |
$0.24B |
0.34 |
| 2009-06-30 |
$0.10B |
$0.23B |
0.42 |
| 2009-03-31 |
$0.09B |
$0.21B |
0.43 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.416B |
$1.121B |
|
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
|
